Thank you. And again, welcome to the Devyser Q3 2024 Earnings Call.
It's a real pleasure to have you all here.
Today, you will be listening to me. Fredrik Alpsten, the Devyser CEO, and Theis Kipling, our Chief Commercial Officer, are responsible for business development. I have also asked our CFO, Sabina Berlin, to join us during the Q&A session. It's very gratifying to see the impact we are having in the field of diagnostics at the moment. We have just returned from the ASHI event, a major conference in the US, and it's clear that many things are going our way at the moment. This applies not only to transportation but also to our other areas of operation. Several milestones were reached during the quarter. We moved all our production and development to our new, proud premises. A number of product registrations were granted around the world. Product development is continuing unabated. The positive signals that we are seeing mean that we invested significantly more during the quarter and the period than last year. Today we embark on a journey through our Q3 results. The second part of the presentation will be dedicated to the highlights, key achievements from the quarter, and we will also discuss the commercial outlook. Organic growth for the quarter was low. Revenue amounted to 48.7 million, which is an organic growth compared to the same quarter of last year of 4% in USD and 7% in local currency. This is lower than we would have liked. But as we have explained, I think, in more or less all our quarterly presentations during the recent years. The figures for some individual quarters may be better or worse than others. The most important thing is that we are expecting the strong growth trend that we have seen in recent years to continue. I would also like to comment. Q3 is considered a holiday quarter for Southern Europe. And as you know, we have significant sales in the southern part of Europe. However, last year we suddenly had the best quarter ever during Q3. And that's one reason: the inventory built up by Thermo Fisher during that quarter. With our innovative products, high market growth, a well-suited commercial organization that we have heavily invested in over the last quarters, and some of the best commercial partners, we are confident that the positive sales trend we have seen in recent years will not only continue but also strengthen. I said we may face individual quarters that do not perform as well, but the overall trend is crystal clear. Our sales are still on a significant upward trajectory, with most quarters expected to be record-breaking. During the quarter, we performed well in our direct markets in Europe and we can see continued opportunities to grow even further here. Our performance in our distributed markets in Europe, the Middle East, Africa, and Asia remains strong. The collaboration with Thermo Fisher is developing very well, and we are very satisfied with it. The low sales during the quarter should not be interpreted as a reduced commitment on our part, but rather as irregular purchasing patterns. We see a continued strong focus from Thermo Fisher on our products and our collaboration. Europe grew by 27% compared with the previous 12 months.
Asia Pacific grew by 43% compared with the previous 12 months. During the last 12 to 18 months, we have signed up quite a few new distributors in Asia, and some of them have now started to generate revenue. The sales in North and South America were low compared with last year. However, we are very optimistic about North America and are currently investing heavily in this market. The potential in North America is massive, and we have just started to penetrate this market. North America will be one of our top priorities for the near, mid, and long term. Our direct sales represented about 75%, and our distributor sales represented 25% of total revenue for the quarter and for the last 12 months. However, as sales through Thermo Fisher Scientific are increasing and new distributors in regions like Asia and the Middle East are added, we may see an increased distributor share of revenue going forward. Talking about Thermo Fisher, I'm glad to report today also that we in October achieved our best quarter ever and that will be reported as revenue in Q4. One of Devyser's strengths is its business model. We have very high gross margins because we sell only consumables and software, not equipment. Over the last few years, we have increased the gross margin from around 75% to about 80%. The reason is a scalable production process and our ability to increase prices, as previously communicated, we decided in spring 2023 to move to a bigger facility to enable higher product volumes and automate the production processes. The move to our new facility has taken place mainly during the second and third quarters of 2024. We have worked extensively to build up the production and R&D parts of the facility. As with all certified and regulated industries, this must be done by the book, documented, validated, and verified. It must be approved by the regulatory authorities and notified bodies when ready. Everything is now ready, and we will have the inauguration of the new facility on November 6th. All work to finalize the new facility has been costly. Cost was negatively impacted in both the second and third quarters. That's the reason why the gross margin has decreased from 85% to 72%. The investment in our new facility will help us to drive down production costs in the future, even further, and help us continue automating the production processes and accordingly increase our gross margins over the long run. It should also be mentioned that to minimize risk, we decided to rent both facilities, both the old one and the new one, during the full year of 2024. This means that we go into 2025. We will not pay rent for the old facility. The quarter's EBIT was more or less in line with our expectations. It amounted to -24,000,006 compared with -8 million. Same quarter last year. The lower result is, among other things, caused by costs associated with the move to the new premises. The lower result can also be derived from increased costs for our expansion in North America and costs for incentive programs resulting from the favorable share price development. However, we are not completely satisfied with the overall expense development. As a rapidly growing company, it's sometimes difficult to maintain. Maintain total cost control to speed up the route to profitability. We have reviewed the cost base in the company during the third quarter and carried out some organizational changes. Costs for this have been charged to the quarter's result. We are convinced that the positive earnings development that we saw in 2023 will continue, and that we will reach our financial goal of an EBIT margin exceeding 20%, sometime between 2024 and 2026. Devyser has a very strong financial position, with 171 million in cash at the end of the quarter and no interest-bearing debts. With that, I'll turn it over to Theis Kipling.